NASDAQ:INTS Intensity Therapeutics Q3 2025 Earnings Results & Report $3.06 -0.02 (-0.49%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Intensity Therapeutics met analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$1.50 versus the -$1.50 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeAfter Market ClosesConference Call7:00 AM ET Intensity Therapeutics EPS ResultsActual EPS-$1.50Consensus EPS -$1.50Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersIntensity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Intensity Therapeutics Q3 2025 Earnings FAQ Did Intensity Therapeutics beat earnings estimates for Q3 2025? Intensity Therapeutics (NASDAQ:INTS) reported earnings of -$1.50 per share for Q3 2025, matching the consensus estimate of -$1.50. The report was announced on Thursday, November 6, 2025. Intensity Therapeutics Earnings HeadlinesWhat is HC Wainwright's Estimate for INTS FY2026 Earnings?November 12, 2026 | americanbankingnews.comBrookline Capital Markets Forecasts INTS FY2026 EarningsNovember 12, 2026 | americanbankingnews.comBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.November 16 at 1:00 AM | Paradigm Press (Ad)Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call TranscriptNovember 7, 2026 | seekingalpha.comIntensity (INTS) Q3 2026 Earnings Call TranscriptNovember 5, 2026 | finance.yahoo.comIntensity Therapeutics, Inc Loss At -$3.544 Mln In Q3November 5, 2026 | rttnews.comSee More Intensity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email. Email Address About Intensity TherapeuticsIntensity Therapeutics (NASDAQ:INTS), Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response. The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors. Founded in 2012, Intensity Therapeutics is led by founder and Chief Executive Officer Lewis Barger. Its work is focused on developing and clinically testing its intratumoral treatment platform.View Intensity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.